Transitions From Daily Dovato to Long-Acting Cabenuva Wanted by Patients With HIV

Many people with HIV want to transition from viral suppression with daily oral Dovato to long-acting injectable ...

JULY 23, 2025

Real-World Data Show Continued Virologic Suppression With Cabenuva

At CROI 2025, new research has shown high rates of continued virologic suppression with cabotegravir-rilpivirine ...

MARCH 25, 2025

Long-Acting Injectable Cabenuva Shows Strong Results in Adolescents

Data from the IMPAACT 2017/MOCHA study support the use of long-acting Cabenuva among virologically suppressed ...

JULY 26, 2024

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Before 2021, oral medication was the only option for HIV prevention and treatment, but adherence has always been a ...

JUNE 27, 2024

CAB+RPV Long-Acting Injections Effective as ART

Cabenuva long-acting injections are effective at controlling HIV, with 96% of users maintaining a viral load of ...

DECEMBER 21, 2023

FDA: Cabenuva No Longer Requires Oral Lead-In Period

Because of the long half-life of the long-acting ART, the FDA originally called for oral dosing for a period before ...

MARCH 25, 2022

FDA Grants New Indication for Cabenuva for Every-8–Week Dosing

The FDA extended the time between shots of Cabenuva to every two months to treat HIV-1 infection in virologically ...

FEBRUARY 1, 2022

Cabenuva Implementation Successful in a Variety of HIV Clinics

Health care teams from a variety of HIV clinics in the United States reported that optimal implementation of ...

JULY 22, 2021